Compare TYRA & TNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | TNC |
|---|---|---|
| Founded | 2018 | 1870 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 1994 |
| Metric | TYRA | TNC |
|---|---|---|
| Price | $25.23 | $66.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $47.50 | ★ $79.00 |
| AVG Volume (30 Days) | ★ 1.0M | 156.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.45 |
| Revenue | N/A | ★ $1,137,600,000.00 |
| Revenue This Year | N/A | $5.77 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | ★ N/A | $148.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.38 | $60.18 |
| 52 Week High | $40.65 | $91.93 |
| Indicator | TYRA | TNC |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 34.81 |
| Support Level | $24.58 | $64.88 |
| Resistance Level | $27.02 | $88.96 |
| Average True Range (ATR) | 2.07 | 2.20 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 61.06 | 9.62 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.